Navigation Links
MINRAD International, Inc. to Discuss 2008 Second Quarter Financial Results on Thursday, August 14, 2008
Date:8/4/2008

ORCHARD PARK, N.Y., Aug. 4 /PRNewswire-FirstCall/ -- MINRAD International, Inc. (Amex: BUF) announced today that the Company will hold an investor conference call to discuss second quarter 2008 financial results on Thursday, August 14, 2008 at 4:30 PM ET. The Company will release second quarter 2008 results prior to the call on Thursday, August 14, 2008.

The toll free call in number in the United States is 866-866-1333. The international call in number is 404-260-1421.

Contact: Charles R. Trego, Jr., Chief Financial Officer

ctrego@minrad.com

(716) 855-1068

http://www.minrad.com

About the Company

MINRAD International, Inc. is an interventional pain management company with real-time image guidance and anesthesia and analgesia product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website, http://www.minrad.com.

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, MINRAD International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of MINRAD International's Form 10-KSB-A, filed with the Securities and Exchange Commission on April 21, 2008. Although MINRAD International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.


'/>"/>
SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP
2. MINRAD International, Inc. Announces the Start of the MINRAD International Distributor Meeting in Cape Town, South Africa
3. MINRAD International, Inc. to Discuss 2007 Fourth Quarter and Full Year Financial Results on Monday, March 31, 2008
4. MINRAD International, Inc. Announces 2007 Financial Results
5. MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane
6. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
7. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
8. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
9. Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
10. TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock
11. Chindex International, Inc. Announces Results for the Quarter and Six Months Ended September 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, ... at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of ... acupuncturists to help patients realize their family building goals. Acupuncture helps fertility ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a ... to the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation ... she can for this country. , Nancy attributes her patriotic nature to her WWII ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” ... Day that follows. , “Fred Rides a Train” is the creation of published ... stories since her teen years in Michigan. The "Fred, the Dog" series is her ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... fifth annual Business Architecture Innovation Summit in Reston, VA on March 21-22, 2017. ... will share a range of experiences from a cross-section of industries such as ...
(Date:12/7/2016)... ... December 07, 2016 , ... NuevaCare, a leading home ... is proud to announce new city-specific pages as part of its ambitious website relaunch. ... they often look, first, for local agencies serving their city. The new site has ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... -- Alopexx Oncology, LLC announced data from a Phase I ... composed of interleukin-2 and a CD20-targeting monoclonal antibody. The ... as Rituxan and maintains the activities of both the ... tumor targeting, engagement of the immune system, and induction ... study (abstract #95954) were presented at the 58 th ...
(Date:12/6/2016)... Dec. 6, 2016 Diabetes & Obesity Drug ... and obesity disease cluster is currently dominated by therapeutics ... 2 diabetes mellitus (T2DM), and the majority of the ... products, is attributable to these indications. While products indicated ... presence, there are a large number of these products ...
(Date:12/6/2016)... The pen needles market is projected to reach USD ... 2016, growing at a CAGR of 11.2% during the ... years, the pen needles market has witnessed various technological ... for safety injections in the healthcare industry. These advancements ... with an aim to reduce pain, increase comfort, and ...
Breaking Medicine Technology: